In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA cosmetics enforcement

This article was originally published in The Rose Sheet

Executive Summary

Memorandum of Understanding completed in early June between FDA's Center for Drug Evaluation and Research and Center for Food Safety and Applied Nutrition allows Office of Cosmetics and Colors to "manage enforcement actions" for cosmetic products "whose label or labeling contains structure/function or disease claims," CFSAN Director Levitt announces during mid-year progress report July 17. MoU was "A" list priority for the center in fiscal 2002 (1"The Rose Sheet" Feb. 4, 2001, p. 13). Other "A" list goals for current year were completing color additive certification procedures within an average of five working days and release of a labeling guidance on alpha hydroxcy acid-containing products...

You may also be interested in...

AHA Labeling, CFSAN/CDER MoU Among CFSAN’s Completed Cosmetic Goals

The Center for Food Safety and Applied Nutrition recently renewed a memorandum of understanding with the Center for Drug Evaluation and Research, marking one of two actions completed by the Office of Cosmetics & Colors in the first nine months of the fiscal year (ending Sept. 30)

FDA Cosmetics Office Aims To Achieve Three “A” List Priorities In 2002

FDA's Office of Cosmetics & Colors will tackle three "A" list items and 10 "B" list goals in fiscal 2002 under the Center for Food Safety & Applied Nutrition's program priorities report issued Jan. 28

ViiV Anticipates 10%-15% Switchover To Long-Term HIV Option Cabenuva

The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts